Home
NewsNewsConceivable Life Sciences' AURA, world's first AI-powered automated IVF lab, has successfully delivered 18 healthy babies since April 2025. The revolutionary robotic system automates 200+ IVF steps with unprecedented precision, promising to make fertility treatment more accessible, affordable, and consistent while eliminating human error in embryo creation.
In a development that sounds like science fiction but is very much our reality, the world has witnessed the birth of its first AI-assisted babies. This isn't about algorithms predicting genetic outcomes or virtual consultations this is about artificial intelligence and robotics physically creating life, one embryo at a time.
Conceivable Life Sciences, a groundbreaking startup that recently secured $50 million in funding, has developed AURA, World's First AI-Powered Automated IVF Lab process from start to finish. Since April 2025, 18 healthy babies have been born using this revolutionary technology, marking a pivotal moment in reproductive medicine.
The significance of this achievement cannot be overstated. For decades, IVF has been a delicate, manual procedure requiring extraordinary precision from fertility specialists. It's essentially single-cell surgery performed under a microscope, where doctors manually manipulate eggs and sperm with instruments finer than human hair. One trembling hand, one moment of fatigue, one miscalculation and an entire cycle can fail, taking with it the hopes and dreams of prospective parents.
Aura transforms this high-stakes process through a combination of artificial intelligence, advanced robotics, and machine vision technology. The system handles over 200 distinct steps in the IVF process with robotic precision, from initial fertilization through to embryo cultivation. Unlike human practitioners, Aura doesn't experience fatigue, doesn't have shaking hands, and eliminates the randomness inherent in manual procedures.
This isn't theoretical technology waiting for approval or years of testing. The proof is already here: 18 healthy babies born, with another 100-patient trial currently underway. Early reports from doctors involved in these trials describe the results as "very promising," suggesting we're on the cusp of a fundamental shift in how fertility treatment is delivered.
Beyond the technological marvel, Aura addresses a critical accessibility issue in fertility care. Currently, a single IVF cycle costs between $12,000 and $25,000 in the United States, and success is far from guaranteed. Many couples require multiple cycles, pushing the total cost well beyond $50,000 or even $100,000. This financial barrier means that for millions of people, biological parenthood remains an impossible dream.
By standardizing and automating the process, AI-driven systems like Aura promise to make fertility treatment cheaper, faster, and more consistent. When every step is performed with identical precision, success rates should theoretically improve while costs decrease. We could be looking at the democratization of fertility care, making it accessible to families who previously couldn't afford it.
There's something profoundly poetic yet unsettling about this development. Creating life is perhaps the most intimate, human experience imaginable. Now, we're entrusting that process to machines and algorithms. It raises philosophical questions about the nature of conception, the role of technology in our most personal moments, and what it means to be human in an increasingly automated world.
Yet for couples struggling with infertility, a condition affecting millions worldwide, these philosophical concerns may pale in comparison to the possibility of holding their own child. If AI can help where human hands have failed, is that not a triumph of human ingenuity itself?
Conceivable Life Sciences plans to bring AURA, World's First AI-Powered Automated IVF Lab to the United States next year, potentially transforming fertility care from an art into a precise, data-driven science. If successful, we may be witnessing the beginning of the end of infertility as an insurmountable medical challenge.
For the first time in human history, artificial intelligence isn't just changing how we live our lives it's helping us create new ones. The future of fertility isn't coming; it's already here, and it just had its first birthday.
A new Ipsos survey commissioned by Fertility Matters Canada finds 49% of Canadians with an opinion support a national baseline for IVF funding support, with backing rising to 59% among those aged 18–34. One in eight Canadians say cost has already forced them or someone close to delay or abandon fertility treatment.
Alpha Controls & Instrumentation Inc. has been selected by FertiTech Canada Inc. as its third-party calibration partner for Nilotech temperature probes. The partnership channels Canadian IVF laboratories and fertility clinics using Nilotech equipment to Alpha Controls for professional, accredited calibration services, while FertiTech continues to handle equipment supply and gas sensor calibration.
In the UK, a Ten Minute Rule Bill has been introduced in the Commons to create a legal right to paid time off for fertility treatment, aiming to standardize access to time‑sensitive appointments and reduce reliance on employer discretion. The proposal seeks House permission to proceed and spotlights workplace rights during Fertility Awareness Week.
Columbia University Fertility Center has achieved the first confirmed pregnancy using an AI-guided sperm recovery method in a man with azoospermia, as detailed in The Lancet. The STAR system combined advanced imaging, microfluidics, and robotics to retrieve two viable sperm, enabling embryo creation after prior failed surgical and manual attempts.
British Columbia's free IVF program exhausts 2025 funding within months of launch. At least one approved clinic stops accepting new applications. Applicants face aging-out risks and must wait until spring 2026 for next funding allocation.
Singapore’s MOH approves 13 additional genetic conditions for testing before embryos are implanted during IVF, enhancing reproductive genetic screening options.
National Health Service-funded IVF in England varies across regions in terms of access, cycle definitions, and eligibility. While Integrated Care Boards follow NICE guidelines, local implementation differs to meet specific population needs. Current policy reviews aim to enhance consistency and ensure continued access to fertility services across England.
